Evidence map›Paper›PMID 27912889›Full record

ReviewFertility and sterility2016

Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause.

Shannon D Sullivan, Philip M Sarrel, Lawrence M Nelson

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Fertility and sterility, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06357442 (Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Continuous Oral Micronized Progesterone Versus the Etonogestrel Implant), which is not on this map. Cited by 202 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
202citing papers in PubMed, 9 pooled it
17.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06357442 recruitingnot on this mapstarted 2024, after this paper: background citation

Assessment of Endometrial Thickness Among Adolescent and Young Adult Patients on Estrogen Replacement Therapy Using Continuous Oral Micronized Progesterone Versus the Etonogestrel Implant: a Prospective Pilot Study

Typeobservational_patient_registrySponsorUniversity of Colorado, DenverRan2024 to 2026Enrolled34ConditionsPrimary Ovarian Insufficiency, Hypogonadotropic Hypogonadism, Hormone Replacement Therapy
3 · Its place in the literature

Who cites it

202 citing papers in PubMed, 9 syntheses or guidelines pooled it, 487 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Guideline
  10. Hormone therapy (HT) in women with premature ovarian insufficiency or early menopause: Time to think of a new paradigm for healthy aging. A joint FIGO and IMS position paper.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article

142 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Shannon D SullivanU.S. Food and Drug Administration, Silver Spring, Maryland.
Philip M SarrelObstetrics, Gynecology, and Reproductive Sciences and Psychiatry, Yale University, New Haven, Connecticut.
Lawrence M NelsonIntramural Research Program, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. Electronic address: lawrence_nelson@nih.gov.
Office of Extramural Research · USUnited States Food and Drug Administration · USYale University · US

Funding

Preconception Health and Reproductive Natural HistoryZIAHD000633 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI NELSON, LAWRENCE M · 2009 to 2016
$7.1M
OVARIAN FOLLICULOGENESISZ01HD000633 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI NELSON, LAWRENCE M · 1991 to 2008
$3.8M
Intramural NIH HHS Z01 HD000633
6 · The paper itself

Abstract

Primary ovarian insufficiency (POI) is a rare but important cause of ovarian hormone deficiency and infertility in women. In addition to causing infertility, POI is associated with multiple health risks, including bothersome menopausal symptoms, decreased bone density and increased risk of fractures, early progression of cardiovascular disease, psychologic impact that may include depression, anxiety, and decreased perceived psychosocial support, potential early decline in cognition, and dry eye syndrome. Appropriate hormone replacement therapy (HRT) to replace premenopausal levels of ovarian sex steroids is paramount to increasing quality of life for women with POI and ameliorating associated health risks. In this review, we discuss POI and complications associated with this disorder, as well as safe and effective HRT options. To decrease morbidity associated with POI, we recommend using HRT formulations that most closely mimic normal ovarian hormone production and continuing HRT until the normal age of natural menopause, ∼50 years. We address special populations of women with POI, including women with Turner syndrome, women with increased risk of breast or ovarian cancer, women approaching the age of natural menopause, and breastfeeding women.

Indexed as

AdultEstrogen Replacement TherapyFemaleFertility Agents, FemaleHumansInfertility, FemaleMenopause, PrematureMiddle AgedPatient SelectionPrimary Ovarian InsufficiencyRisk AssessmentRisk FactorsTreatment OutcomeFertility Agents, Femaleandrogenearly menopauseestrogenhormone replacement therapymanagementmenopausal hormone therapymorbiditymortalitypremature menopausepremature ovarian failurePrimary ovarian insufficiencyprogestin

Identifiers

PMID27912889
PMCPMC5137796
OpenAlexW2559178581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.